Daniel J Gottlieb1, Naresh M Punjabi, Reena Mehra, Sanjay R Patel, Stuart F Quan, Denise C Babineau, Russell P Tracy, Michael Rueschman, Roger S Blumenthal, Eldrin F Lewis, Deepak L Bhatt, Susan Redline. 1. From the Veterans Affairs Boston Healthcare System (D.J.G., D.L.B.), Brigham and Women's Hospital (D.J.G., S.R.P., S.F.Q., M.R., E.F.L., D.L.B., S.R.), Harvard Medical School (D.J.G., S.R.P., S.F.Q., E.F.L., D.L.B., S.R.), Boston University School of Medicine (D.J.G.), and Beth Israel Deaconess Medical Center (S.R.P., S.R.) - all in Boston; Johns Hopkins University, Baltimore (N.M.P., R.S.B.); Cleveland Clinic (R.M.) and Case Western Reserve University (R.M., D.C.B.) - both in Cleveland; and the University of Vermont, Colchester (R.P.T.).
Abstract
BACKGROUND:Obstructive sleep apnea is associated with hypertension, inflammation, and increased cardiovascular risk. Continuous positive airway pressure (CPAP) reduces blood pressure, but adherence is often suboptimal, and the benefit beyond management of conventional risk factors is uncertain. Since intermittent hypoxemia may underlie cardiovascular sequelae of sleep apnea, we evaluated the effects of nocturnal supplemental oxygen and CPAP on markers of cardiovascular risk. METHODS: We conducted a randomized, controlled trial in which patients with cardiovascular disease or multiple cardiovascular risk factors were recruited from cardiology practices. Patients were screened for obstructive sleep apnea with the use of the Berlin questionnaire, and home sleep testing was used to establish the diagnosis. Participants with an apnea-hypopnea index of 15 to 50 events per hour were randomly assigned to receive education on sleep hygiene and healthy lifestyle alone (the control group) or, in addition to education, either CPAP or nocturnal supplemental oxygen. Cardiovascular risk was assessed at baseline and after 12 weeks of the study treatment. The primary outcome was 24-hour mean arterial pressure. RESULTS: Of 318 patients who underwent randomization, 281 (88%) could be evaluated for ambulatory blood pressure at both baseline and follow-up. On average, the 24-hour mean arterial pressure at 12 weeks was lower in the group receiving CPAP than in the control group (-2.4 mm Hg; 95% confidence interval [CI], -4.7 to -0.1; P=0.04) or the group receiving supplemental oxygen (-2.8 mm Hg; 95% CI, -5.1 to -0.5; P=0.02). There was no significant difference in the 24-hour mean arterial pressure between the control group and the group receiving oxygen. A sensitivity analysis performed with the use of multiple imputation approaches to assess the effect of missing data did not change the results of the primary analysis. CONCLUSIONS: In patients with cardiovascular disease or multiple cardiovascular risk factors, the treatment of obstructive sleep apnea with CPAP, but not nocturnal supplemental oxygen, resulted in a significant reduction in blood pressure. (Funded by the National Heart, Lung, and Blood Institute and others; HeartBEAT ClinicalTrials.gov number, NCT01086800 .).
RCT Entities:
BACKGROUND:Obstructive sleep apnea is associated with hypertension, inflammation, and increased cardiovascular risk. Continuous positive airway pressure (CPAP) reduces blood pressure, but adherence is often suboptimal, and the benefit beyond management of conventional risk factors is uncertain. Since intermittent hypoxemia may underlie cardiovascular sequelae of sleep apnea, we evaluated the effects of nocturnal supplemental oxygen and CPAP on markers of cardiovascular risk. METHODS: We conducted a randomized, controlled trial in which patients with cardiovascular disease or multiple cardiovascular risk factors were recruited from cardiology practices. Patients were screened for obstructive sleep apnea with the use of the Berlin questionnaire, and home sleep testing was used to establish the diagnosis. Participants with an apnea-hypopnea index of 15 to 50 events per hour were randomly assigned to receive education on sleep hygiene and healthy lifestyle alone (the control group) or, in addition to education, either CPAP or nocturnal supplemental oxygen. Cardiovascular risk was assessed at baseline and after 12 weeks of the study treatment. The primary outcome was 24-hour mean arterial pressure. RESULTS: Of 318 patients who underwent randomization, 281 (88%) could be evaluated for ambulatory blood pressure at both baseline and follow-up. On average, the 24-hour mean arterial pressure at 12 weeks was lower in the group receiving CPAP than in the control group (-2.4 mm Hg; 95% confidence interval [CI], -4.7 to -0.1; P=0.04) or the group receiving supplemental oxygen (-2.8 mm Hg; 95% CI, -5.1 to -0.5; P=0.02). There was no significant difference in the 24-hour mean arterial pressure between the control group and the group receiving oxygen. A sensitivity analysis performed with the use of multiple imputation approaches to assess the effect of missing data did not change the results of the primary analysis. CONCLUSIONS: In patients with cardiovascular disease or multiple cardiovascular risk factors, the treatment of obstructive sleep apnea with CPAP, but not nocturnal supplemental oxygen, resulted in a significant reduction in blood pressure. (Funded by the National Heart, Lung, and Blood Institute and others; HeartBEAT ClinicalTrials.gov number, NCT01086800 .).
Authors: Yüksel Peker; Jan Hedner; Jeanette Norum; Holger Kraiczi; Jan Carlson Journal: Am J Respir Crit Care Med Date: 2002-07-15 Impact factor: 21.405
Authors: Susan Redline; Gayane Yenokyan; Daniel J Gottlieb; Eyal Shahar; George T O'Connor; Helaine E Resnick; Marie Diener-West; Mark H Sanders; Philip A Wolf; Estella M Geraghty; Tauqeer Ali; Michael Lebowitz; Naresh M Punjabi Journal: Am J Respir Crit Care Med Date: 2010-03-25 Impact factor: 21.405
Authors: Daniel Norman; José S Loredo; Richard A Nelesen; Sonia Ancoli-Israel; Paul J Mills; Michael G Ziegler; Joel E Dimsdale Journal: Hypertension Date: 2006-04-03 Impact factor: 10.190
Authors: Joaquín Durán-Cantolla; Felipe Aizpuru; Jose María Montserrat; Eugeni Ballester; Joaquín Terán-Santos; Jose Ignacio Aguirregomoscorta; Mónica Gonzalez; Patricia Lloberes; Juan Fernando Masa; Mónica De La Peña; Santiago Carrizo; Mercedes Mayos; Ferrán Barbé Journal: BMJ Date: 2010-11-24
Authors: Lucas M Donovan; Laura C Feemster; Edmunds M Udris; Matthew F Griffith; Laura J Spece; Brian N Palen; Ken He; Sairam Parthasarathy; Kingman P Strohl; Vishesh K Kapur; David H Au Journal: J Clin Sleep Med Date: 2019-01-15 Impact factor: 4.062
Authors: Dominik Linz; Holger Woehrle; Thomas Bitter; Henrik Fox; Martin R Cowie; Michael Böhm; Olaf Oldenburg Journal: Clin Res Cardiol Date: 2015-04-23 Impact factor: 5.460
Authors: Sina A Gharib; Amanda L Hurley; Michael J Rosen; James C Spilsbury; Amy E Schell; Reena Mehra; Sanjay R Patel Journal: Sleep Date: 2020-06-15 Impact factor: 5.849
Authors: Susan Redline; Si Baker-Goodwin; Jessie P Bakker; Matthew Epstein; Sherry Hanes; Mark Hanson; Zinta Harrington; James C Johnston; Vishesh K Kapur; David Keepnews; Emily Kontos; Andy Lowe; Judith Owens; Kathy Page; Nancy Rothstein Journal: J Clin Sleep Med Date: 2016-07-15 Impact factor: 4.062
Authors: Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White Journal: Hypertension Date: 2018-11 Impact factor: 10.190
Authors: Juan F Masa; Jaime Corral; Auxiliadora Romero; Candela Caballero; Joaquin Terán-Santos; Maria L Alonso-Álvarez; Teresa Gomez-Garcia; Mónica González; Soledad López-Martínez; Pilar De Lucas; José M Marin; Sergi Marti; Trinidad Díaz-Cambriles; Eusebi Chiner; Miguel Merchan; Carlos Egea; Ana Obeso; Babak Mokhlesi Journal: J Clin Sleep Med Date: 2016-10-15 Impact factor: 4.062